Soleno Therapeutics (SLNO) Gains from Investment Securities (2013 - 2023)
Soleno Therapeutics' (SLNO) quarterly Gains from Investment Securities came in at -$470000.0 in Q4 2023, down 47100.0% year-on-year from N/an in Q4 2022, and down 171.98% on a QoQ basis from $653000.0 in Q3 2023.
Soleno Therapeutics (SLNO) Gains from Investment Securities (2013 - 2023) Analysis & Trends
Soleno Therapeutics (SLNO) has 11 years of Gains from Investment Securities data on file, last reported at -$470000.0 in Q4 2023.
- On a quarterly basis, Gains from Investment Securities fell 47100.0% year-over-year to -$470000.0 in Q4 2023; TTM through Dec 2024 was -$470000.0, a 356.83% decrease from a year earlier, with the FY2023 full-year figure at $182000.0, up 706.67% from the prior year.
- Gains from Investment Securities for Q4 2023 stood at -$470000.0, down from $653000.0 in the prior quarter.
- Over the last five years, Gains from Investment Securities for SLNO reached as high as $7.9 million in Q4 2019 and fell as low as -$7.1 million in Q3 2019.
- Historically, Gains from Investment Securities has averaged -$264684.2 across 5 years, with a median of -$27000.0 in 2022.
- On a YoY basis, Gains from Investment Securities climbed as much as 32750.0% in 2023 and fell as far as 47100.0% in 2023.
- Year by year, Gains from Investment Securities stood at $7.9 million in 2019, then plunged by 164.67% to -$5.1 million in 2020, then jumped by 97.28% to -$139000.0 in 2021, then surged by 100.72% to $1000.0 in 2022, then sank by 47100.0% to -$470000.0 in 2023.
- Per Business Quant data, the three most recent Gains from Investment Securities figures were -$470000.0 in Q4 2023, $653000.0 in Q3 2023, and -$1000.0 in Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,132.22 Bn | 67,131.94 Bn | - |
| 2 | Nanobiotix | 1,910.87 Bn | 1,910.81 Bn | - |
| 3 | Akari Therapeutics | 989.71 Bn | 989.71 Bn | - |
| 4 | BeOne Medicines | 471.60 Bn | 466.80 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.71 Bn | 114.46 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.83 Bn | 61.07 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.74 Bn | 62.74 Bn | - |
| 8 | Argenx Se | 55.83 Bn | 50.65 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.33 Bn | 34.32 Bn | 959.66 Mn |
| 10 | Soleno Therapeutics | 874.25 Mn | 618.67 Mn | 93.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | -470,000.00 |
| Dec 31, 2023 | -470,000.00 |
| Sep 30, 2023 | 653,000.00 |
| Sep 30, 2023 | 653,000.00 |
| Jun 30, 2023 | -1,000.00 |
| Jun 30, 2023 | -1,000.00 |
| Dec 31, 2022 | 1,000.00 |
| Dec 31, 2022 | 1,000.00 |
| Sep 30, 2022 | -2,000.00 |
| Sep 30, 2022 | -2,000.00 |
| Jun 30, 2022 | -2,000.00 |
| Jun 30, 2022 | -2,000.00 |
| Mar 31, 2022 | -27,000.00 |
| Mar 31, 2022 | -27,000.00 |
| Dec 31, 2021 | -139,000.00 |
| Dec 31, 2021 | -139,000.00 |
| Sep 30, 2021 | -112,000.00 |
| Sep 30, 2021 | -112,000.00 |
| Jun 30, 2021 | -56,000.00 |
| Jun 30, 2021 | -56,000.00 |